Supplementary Table 5. Primary and secondary outcomes by glycemic trajectory group in the expanded cohort with at least three glucose measurements

Outcomes	Normoglycemic (Group 1, n=115)	Persistently elevated stable (Group 2, n=178)	Variable hyperglycemic (Group 3, n=68)	*P**
3-month mRS (shift analysis)	2 (1–3)	4 (1–5)	3 (1–4)	<0.001
Functional independence (mRS 0–2)	74 (64.3)	68 (38.2)	28 (41.2)	<0.001
Excellent outcome (mRS 0–1)	52 (45.2)	50 (28.1)	21 (30.9)	0.009
Poor outcome (mRS 4–6)	27 (23.5)	90 (50.6)	32 (47.1)	<0.001
Symptomatic hemorrhagic transformation on day 5[‡]	0 (0.0)	5 (2.9)	2 (3.0)	0.139
Cerebral infarct volume (mL)				
Day 1	23 (7–67)	51 (15–152)	22 (6–91)	0.002
Day 5	27 (12–92)	69 (24–192)	36 (15–135)	<0.001
Week 12	9 (2–59)	20 (3–55)	9 (4–62)	0.393

Values are presented as median (interquartile range) or n (%).
mRS, modified Rankin Scale.
**P*-value by Cochran-Mantel-Haenszel shift test, chi-square test, Fisher's exact test, and Kruskal-Wallis test; [‡]Data were missing in 11 patients; percentages were calculated among the patients with available data.

https://doi.org/10.5853/jos.2026.03867